Calls for price cuts on cancer meds

If the government says cancer drugs aren't worth the cost, then what? Ask drugmakers to cut their prices. After the U.K.'s National Institute for Health and Clinical Excellence rejected four kidney-cancer treatments yesterday, advocates immediately ramped up pressure on pharmaceutical companies to lower their price tags. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.